CureVac (CVAC) Competitors

$4.66 0.00 (0.00%)

As of 05/4/2026

CVAC vs. INDV, CRNX, AMRX, NNNN, and VKTX

Should you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Indivior (INDV), Crinetics Pharmaceuticals (CRNX), Amneal Pharmaceuticals (AMRX), Anbio Biotechnology (NNNN), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry.

How does CureVac compare to Indivior?

CureVac (NASDAQ:CVAC) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

: CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
: 17.3% of CureVac shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: CureVac presently has a consensus target price of $6.83, indicating a potential upside of 46.64%. Indivior has a consensus target price of $39.33, indicating a potential downside of 0.69%. Given CureVac's higher probable upside, analysts plainly believe CureVac is more favorable than Indivior.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
1 Sell rating(s)
4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.80
Indivior
0 Sell rating(s)

1 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
3.00
: In the previous week, Indivior had 20 more articles in the media than CureVac. MarketBeat recorded 20 mentions for Indivior and 0 mentions for CureVac. Indivior's average media sentiment score of 0.81 beat CureVac's score of 0.00 indicating that Indivior is being referred to more favorably in the news media.
Company Overall Sentiment
CureVac Neutral
Indivior Positive
: Indivior has higher revenue and earnings than CureVac. CureVac is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CureVac $70.74M 14.78 $175.50M $0.72 6.47
Indivior $1.24B 3.90 $210M $1.95 20.31
: CureVac has a net margin of 199.92% compared to Indivior's net margin of 19.44%. CureVac's return on equity of -23.03% beat Indivior's return on equity.
Company Net Margins Return on Equity Return on Assets
CureVac 199.92% -23.03% -19.09%
Indivior 19.44% -219.26% 29.40%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Overall Sentiment
CureVac	Neutral
Indivior	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Indivior	$1.24B	3.90	$210M	$1.95	20.31

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Indivior	19.44%	-219.26%	29.40%

Summary

Indivior beats CureVac on 11 of the 17 factors compared between the two stocks.

How does CureVac compare to Crinetics Pharmaceuticals?

CureVac (NASDAQ:CVAC) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

: CureVac presently has a consensus target price of $6.83, suggesting a potential upside of 46.64%. Crinetics Pharmaceuticals has a consensus target price of $76.75, suggesting a potential upside of 88.28%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than CureVac.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
1 Sell rating(s)
4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.80
Crinetics Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.90
: CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.
: CureVac has a net margin of 199.92% compared to Crinetics Pharmaceuticals' net margin of -6,046.22%. CureVac's return on equity of -23.03% beat Crinetics Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
CureVac 199.92% -23.03% -19.09%
Crinetics Pharmaceuticals -6,046.22% -41.46% -37.43%
: 17.3% of CureVac shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: CureVac has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CureVac $70.74M 14.78 $175.50M $0.72 6.47
Crinetics Pharmaceuticals $7.70M 558.48 -$465.32M -$4.94 N/A
: In the previous week, Crinetics Pharmaceuticals had 12 more articles in the media than CureVac. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 0 mentions for CureVac. Crinetics Pharmaceuticals' average media sentiment score of 0.96 beat CureVac's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
CureVac Neutral
Crinetics Pharmaceuticals Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Crinetics Pharmaceuticals	-6,046.22%	-41.46%	-37.43%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Crinetics Pharmaceuticals	$7.70M	558.48	-$465.32M	-$4.94	N/A

Company	Overall Sentiment
CureVac	Neutral
Crinetics Pharmaceuticals	Positive

Summary

Crinetics Pharmaceuticals beats CureVac on 9 of the 17 factors compared between the two stocks.

How does CureVac compare to Amneal Pharmaceuticals?

CureVac (NASDAQ:CVAC) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

: In the previous week, Amneal Pharmaceuticals had 7 more articles in the media than CureVac. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 0 mentions for CureVac. Amneal Pharmaceuticals' average media sentiment score of 0.75 beat CureVac's score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
CureVac Neutral
Amneal Pharmaceuticals Positive
: CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.
: CureVac has a net margin of 199.92% compared to Amneal Pharmaceuticals' net margin of 4.53%. CureVac's return on equity of -23.03% beat Amneal Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
CureVac 199.92% -23.03% -19.09%
Amneal Pharmaceuticals 4.53% -276.67% 7.60%
: CureVac currently has a consensus target price of $6.83, suggesting a potential upside of 46.64%. Amneal Pharmaceuticals has a consensus target price of $15.00, suggesting a potential upside of 11.67%. Given CureVac's higher probable upside, equities research analysts clearly believe CureVac is more favorable than Amneal Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
1 Sell rating(s)
4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.80
Amneal Pharmaceuticals
0 Sell rating(s)

2 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.75
: 17.3% of CureVac shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: CureVac has higher earnings, but lower revenue than Amneal Pharmaceuticals. CureVac is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CureVac $70.74M 14.78 $175.50M $0.72 6.47
Amneal Pharmaceuticals $3.02B 1.40 $72.06M $0.38 35.35

Company	Overall Sentiment
CureVac	Neutral
Amneal Pharmaceuticals	Positive

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Amneal Pharmaceuticals	4.53%	-276.67%	7.60%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Amneal Pharmaceuticals	$3.02B	1.40	$72.06M	$0.38	35.35

Summary

Amneal Pharmaceuticals beats CureVac on 9 of the 16 factors compared between the two stocks.

How does CureVac compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and CureVac (NASDAQ:CVAC) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

: CureVac has a net margin of 199.92% compared to Anbio Biotechnology's net margin of 0.00%. Anbio Biotechnology's return on equity of 0.00% beat CureVac's return on equity.
Company Net Margins Return on Equity Return on Assets
Anbio Biotechnology N/A N/A N/A
CureVac 199.92% -23.03% -19.09%
: Anbio Biotechnology has a beta of 4.71, suggesting that its share price is 371% more volatile than the S&P 500. Comparatively, CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.
: CureVac has a consensus target price of $6.83, suggesting a potential upside of 46.64%. Given CureVac's stronger consensus rating and higher possible upside, analysts clearly believe CureVac is more favorable than Anbio Biotechnology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anbio Biotechnology
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
CureVac
1 Sell rating(s)

4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.80
: CureVac has higher revenue and earnings than Anbio Biotechnology.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anbio Biotechnology $8.65M 493.14 $6.40M N/A N/A
CureVac $70.74M 14.78 $175.50M $0.72 6.47
: In the previous week, Anbio Biotechnology had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Anbio Biotechnology and 0 mentions for CureVac. Anbio Biotechnology's average media sentiment score of 0.64 beat CureVac's score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the media.
Company Overall Sentiment
Anbio Biotechnology Positive
CureVac Neutral
: 17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
CureVac	199.92%	-23.03%	-19.09%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	493.14	$6.40M	N/A	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Company	Overall Sentiment
Anbio Biotechnology	Positive
CureVac	Neutral

Summary

CureVac beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

How does CureVac compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

: Viking Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.
: 76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: CureVac has a net margin of 199.92% compared to Viking Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Viking Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Viking Therapeutics N/A -71.31% -65.35%
CureVac 199.92% -23.03% -19.09%
: CureVac has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A
CureVac $70.74M 14.78 $175.50M $0.72 6.47
: Viking Therapeutics presently has a consensus target price of $95.50, suggesting a potential upside of 205.06%. CureVac has a consensus target price of $6.83, suggesting a potential upside of 46.64%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Viking Therapeutics is more favorable than CureVac.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
1 Sell rating(s)
3 Hold rating(s)

6 Buy rating(s)

3 Strong Buy rating(s)
2.85
CureVac
1 Sell rating(s)

4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.80
: In the previous week, Viking Therapeutics had 32 more articles in the media than CureVac. MarketBeat recorded 32 mentions for Viking Therapeutics and 0 mentions for CureVac. Viking Therapeutics' average media sentiment score of 0.24 beat CureVac's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Viking Therapeutics Neutral
CureVac Neutral

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
CureVac	199.92%	-23.03%	-19.09%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.85
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Company	Overall Sentiment
Viking Therapeutics	Neutral
CureVac	Neutral

Summary

Viking Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.

Get CureVac News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVAC vs. The Competition

Export

Metric	CureVac	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.05B	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	6.47	38.92	29.03	28.47
Price / Sales	14.78	154.75	476.10	60.92
Price / Cash	4.73	57.88	27.62	36.52
Price / Book	1.39	7.03	9.67	6.67
Net Income	$175.50M	$23.62M	$3.55B	$332.53M
7 Day Performance	N/A	3.78%	1.75%	2.03%
1 Month Performance	N/A	7.30%	5.66%	9.23%
1 Year Performance	34.29%	67.15%	34.42%	39.62%

CureVac Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880	Negative News
INDV Indivior	2.8111 of 5 stars	$34.31 +3.3%	$39.33 +14.6%	N/A	$4.05B	$1.24B	20.92	1,051	News Coverage Earnings Report Analyst Revision High Trading Volume
CRNX Crinetics Pharmaceuticals	3.3368 of 5 stars	$38.62 +0.8%	$76.63 +98.4%	N/A	$4.01B	$7.70M	N/A	210	Positive News Upcoming Earnings
AMRX Amneal Pharmaceuticals	3.0724 of 5 stars	$12.57 +0.4%	$15.00 +19.3%	N/A	$3.94B	$3.02B	33.08	8,500
NNNN Anbio Biotechnology	N/A	$27.65 +1.1%	N/A	N/A	$3.94B	$8.65M	N/A	27	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVAC) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CureVac (CVAC) Competitors

CVAC vs. INDV, CRNX, AMRX, NNNN, and VKTX

How does CureVac compare to Indivior?

Summary

How does CureVac compare to Crinetics Pharmaceuticals?

Summary

How does CureVac compare to Amneal Pharmaceuticals?

Summary

How does CureVac compare to Anbio Biotechnology?

Summary

How does CureVac compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CureVac (CVAC) Competitors

CVAC vs. INDV, CRNX, AMRX, NNNN, and VKTX

How does CureVac compare to Indivior?

Summary

How does CureVac compare to Crinetics Pharmaceuticals?

Summary

How does CureVac compare to Amneal Pharmaceuticals?

Summary

How does CureVac compare to Anbio Biotechnology?

Summary

How does CureVac compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools